Skip to main content

Leqvio News

Monthly News Roundup - July 2023

FDA Clears Opill, the First Over-the-Counter (OTC) Oral Birth Control Pill History in women’s health was made in July when the FDA cleared Opill (norgestrel 0.075 mg), the first over-the-counter (...

US FDA Approves Expanded Indication for Leqvio (inclisiran) to Include Treatment of Adults with High LDL-C and Who Are At Increased Risk of Heart Disease

Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to...

FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C)

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

High Cholesterol - Familial Heterozygous, High Cholesterol

Leqvio patient information at Drugs.com